Aprea Therapeutics, Inc.
General ticker "APRE" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $13.1M (TTM average)
Aprea Therapeutics, Inc. does not follow the US Stock Market performance with the rate: -6.8%.
Estimated limits based on current volatility of 7.4%: low 1.00$, high 1.16$
Factors to consider:
- Total employees count: 7 as of 2023
- Top business risk factors: Cybersecurity threats, Operational and conduct risks, Regulatory and compliance, Succession planning, ESG risks
- Current price 25.6% below estimated low
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [1.42$, 4.28$]
- 2025-12-31 to 2026-12-31 estimated range: [0.92$, 2.88$]
Financial Metrics affecting the APRE estimates:
- Positive: with PPE of -1.3 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -76.60 <= 0.33
- Positive: Shareholder equity ratio, % of 80.52 > 63.39
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term APRE quotes
Long-term APRE plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.58MM | $1.50MM |
| Operating Expenses | $113.39MM | $16.06MM | $15.82MM |
| Operating Income | $-113.39MM | $-15.47MM | $-14.32MM |
| Non-Operating Income | $0.73MM | $1.19MM | $1.36MM |
| Interest Expense | $0.45MM | $0.00MM | $0.00MM |
| R&D Expense | $92.42MM | $7.63MM | $9.36MM |
| Income(Loss) | $-112.66MM | $-14.29MM | $-12.96MM |
| Profit(Loss)* | $-112.66MM | $-14.29MM | $-12.96MM |
| Stockholders Equity | $25.64MM | $18.26MM | $19.31MM |
| Assets | $30.16MM | $22.65MM | $23.98MM |
| Operating Cash Flow | $-25.01MM | $-12.18MM | $-13.56MM |
| Capital expenditure | $0.00MM | $0.09MM | $0.02MM |
| Investing Cash Flow | $0.00MM | $-0.09MM | $-0.02MM |
| Financing Cash Flow | $0.68MM | $5.14MM | $14.82MM |
| Earnings Per Share** | $-1,359.80 | $-3.95 | $-2.35 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.